The mutation rates for DNMT3A and TET2 in either gene or both were as high as 92.9% in angioimmunoblastic T cell lymphoma, 80% in chronic myelomonocytic leukemia, 58.4% AML with mutated NPM1 and 57.1% in peripheral T cell lymphoma (Fig. 1b). This evidence concerns the gene TET2 and acute myeloid leukemia.